EGFRvIII-directed CAR-T cell tharapy (Novartis/University of Pennsylvania)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameEGFRvIII-directed CAR-T cell tharapy (Novartis/University of Pennsylvania)
Drug Alias NameCART-EGFRvIIILXF-821
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionT lymphocyte replacementsAnti-EGFRvIIIImmunologic cytotoxicity +[5] 
TargetsEpidermal growth factor receptor variant IIIProgrammed cell death protein 1
Therapy Area/IndicationsGlioblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesNovartis Pharma AgUniversity Of Pennsylvania
China Registration ClassN/A

Develop Information

Active CompaniesNovartis Pharma Ag
Inactive CompaniesN/A
Active IndicationsGlioblastoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A